Apogee Therapeutics, Inc. (APGE) Q3 2025 10-Q Quarterly Report
Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Apogee Therapeutics, Inc. (APGE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Apogee Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New geopolitical risk from conflicts involving Russia, Ukraine, Israel, and Hamas impacting financial markets and capital raising ability
- • Updated financial risk: net loss $186.5M for nine months ended Sep 30, 2025; cash runway now into second half of 2028
Apogee Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$65M
▼ -32.6% YoY▲ +1.6% QoQ
Total Assets
$626M
EPS (Diluted)
$-1.11
▼ -27.6% YoY▲ +1.8% QoQ
Operating Cash Flow
-$54M
▼ -27.6% YoY▲ +12.5% QoQ
Source: XBRL data from Apogee Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Apogee Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.